Europa Trial
General Public Heathcare Professionals Virtual Press Office

New Indication in CAD

EUROPA calendar
ACC 2006 - Posters
ESC 2005 - Symposium
ESC 2005 - Oral sessions
ESC 2005 - Posters
AHA 2004 - Oral Session
ESC 2004 - Hotline
ESC 2004 - Symposium
ACC 2004
ESC 2003

EUROPA study
EUROPA Results
ESC 2003 Hotline - video
Rationale for EUROPA
Rationale for Perindopril
Design & Organisation
EUROPA investigators
EUROPA collaborating centres
EUROPA Recruitment

EUROPA Slide Set
Rationale and Design
Clinical Implications

EUROPA publications

PERSUADE Publications


Background : Coronary Artery Disease
Home : Healthcare professionals : ACC 2006 - Posters
ACC 2006 - Posters

Effects of Perindopril on Long-Term Clinical Outcome of Patients With Coronary Artery Disease and Left Ventricular Function

Michel E. Bertrand, Wilhelm J. Remme, Roberto Ferrari, Jaap W. Deckers, Maarten L. Simoons, Kim M. Fox, Lille Heart Institute, Lille, France

Stable Ischemic Syndrome

Background: Background: The EUROPA trial has demonstrated that perindopril, an ACE inhibitor with high-tissue affinity, was able to significantly decrease the risk of major cardiac events in patients (pts) with stable coronary heart disease (SCAD) without apparent heart failure

Aim: To assess the long-term clinical outcome of pts with SCAD and preserved left ventricular function (left ventricular ejection fraction (LVEF)>40%).

Methods: A retrospective evaluation of LVEF was performed in the EUROPA study population. Among the 12,218 pts of EUROPA, we identified 7,096 (58%) pts who had LVEF measurement before randomization. Two groups of pts were studied: 6,878 (97 %) pts with LVEF > 40% (3,429 received 8 mg of perindopril and 3,449 received a placebo) and 218 pts (3%) with a LVEF 40%), there was a significant relative risk reduction of 16 % of the primary endpoint (a composite of cardiovascular death, non fatal myocardial infarction (MI) and resuscitated cardiac arrest) in the group treated with perindopril (8.3%) in comparison to the group treated with placebo (9.8%): Hazard ratio (HR) =0.84 [95% CI: 0.72-0.99] p=0.033). Similar results were obtained for the first secondary endpoint (total mortality, non-fatal MI, hospital admission for unstable angina and cardiac arrest with successful resuscitation): HR=0.85 [95% CI: 0.76-0.96] p=0.008, for cardiovascular mortality and non fatal MI: HR=0.84 [95% CI: 0.72-0.99] p=0.036. Similar benefits were observed in pts with an LVEF > 40% and a history of previous MI and in pts with an LVEF < 40%.

Conclusions: LVEF was documented in 58% of the EUROPA study population and only 3% had an impaired LV function, confirming that EUROPA pts did not have asymptomatic LV dysfunction. Results in pts with preserved LV function are consistent with those of the whole EUROPA study population and perindopril 8mg is beneficial in all pts with stable coronary artery disease.

Keywords: ACE inhibitor,Prevention,Coronary artery disease


This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information.
This site is published and updated by the EUROPA study investigators. Site last updated March 21st 2006
To report a suspected side-effect with a Servier drug, please click here.
Terms of use - ©2005 EUROPA All rights reserved